Innovent to seek China approval of high-dose obesity shot after Phase 3 hitnews2025-11-20T11:30:31+00:00November 20th, 2025|Endpoints News|
Makary calls for ‘America First’ drug user fee renegotiationsnews2025-11-18T19:14:27+00:00November 18th, 2025|Endpoints News|
Trump Is Wrong About Fentanyl in Almost Every Waynews2025-11-15T12:00:06+00:00November 15th, 2025|The New York Times|
Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipidsnews2025-11-14T17:56:23+00:00November 14th, 2025|Endpoints News|
Chinese biotechs are shedding their fast-follower reputations as innovation surgesnews2025-11-12T18:18:10+00:00November 12th, 2025|Endpoints News|
La búsqueda de China de conquistar el envejecimientonews2025-11-10T18:24:09+00:00November 10th, 2025|The New York Times|
Inside China’s Quest to Defy Aging with Longevity Labs and ‘Immortality Islands’news2025-11-08T10:55:21+00:00November 8th, 2025|The New York Times|
Eccogene targets $150M in HKEX listing for MASH, obesity drugsnews2025-11-07T11:30:06+00:00November 7th, 2025|Endpoints News|
China lifts ban on Illumina’s DNA sequencersnews2025-11-06T03:19:41+00:00November 6th, 2025|Endpoints News|
Cardio biotech Braveheart gets $185M, names Biogen CEO as its chairnews2025-11-05T11:00:13+00:00November 5th, 2025|Endpoints News|
